These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7680206)

  • 1. Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission.
    Fiore JR; Jansson M; Scarlatti G; Angarano G; Caputo SL; Buccoliero G; Rossi P; Fenyö EM; Pastore G
    AIDS; 1993 Jan; 7(1):29-31. PubMed ID: 7680206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
    Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
    AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study.
    Parekh BS; Shaffer N; Pau CP; Abrams E; Thomas P; Pollack H; Bamji M; Kaul A; Schochetman G; Rogers M
    AIDS; 1991 Oct; 5(10):1179-84. PubMed ID: 1786145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
    Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
    J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. The HEC/FIOCRUZ AIDS Clinical Research Group.
    Bongertz V; Guimarães ML; Soares-da-Costa MF; Veloso VG; Bastos FI; Szwarcwald CL; Derrico M; Telles PR; Pilloto JH; João Filho EC; Morgado MG
    J Clin Virol; 1999 Jan; 12(1):27-36. PubMed ID: 10073411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide serology for analysis of the inter- and intra-individual variation in the HIV-1 V3 domain.
    Jansson M; Wahren B; Albert J; Scarlatti G; Franzén L; Kataaha PK; Katabira E; Mubiro F; Wigzell H; Rossi P
    AIDS; 1994 Apr; 8(4):413-21. PubMed ID: 8011244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellin.
    Cattozzo EM; Stocker BA; Radaelli A; De Giuli Morghen C; Tognon M
    J Biotechnol; 1997 Aug; 56(3):191-203. PubMed ID: 9304878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina.
    Calarota SA; Libonatti OV
    Scand J Immunol; 2000 Sep; 52(3):292-7. PubMed ID: 10972906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.
    Devash Y; Matthews TJ; Drummond JE; Javaherian K; Waters DJ; Arthur LO; Blattner WA; Rusche JR
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):307-16. PubMed ID: 2340200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of maternal cytophilic human immunodeficiency virus (HIV)-1 V3 loop peptide-specific antibodies in infants with vertical HIV transmission.
    Wang XP; Oyaizu N; Pahwa S
    Pediatr Res; 1995 Sep; 38(3):384-9. PubMed ID: 7494664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of genetic heterogeneity, antigenicity, and biological characteristics of HIV-1 in a maternal transmitter and nontransmitter patient pair.
    Ayyavoo V; Ugen KE; Fernandes LS; Goedert JJ; Rubinstein A; Williams WV; Weiner DB
    DNA Cell Biol; 1996 Jul; 15(7):571-80. PubMed ID: 8756338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
    Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F
    AIDS; 1995 May; 9(5):435-9. PubMed ID: 7639968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.